Growth Hormone Fragment — Marketed for Fat Loss (Not Recommended)
Matrix Advisory
Source evidence does not support this compound for meaningful fat loss. No strong clinical data in humans. This is a massive waste of money.
HGH Frag 176-191 is a modified fragment of the human growth hormone molecule (amino acids 176–191). It is marketed as a fat-loss peptide that retains the lipolytic properties of GH without the growth-promoting or diabetogenic effects. Source assessment: it does not produce meaningful fat loss in practice.
Mimics the lipolytic (fat-burning) region of the GH molecule. In theory, it stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or growth. In practice, the fragment is rapidly degraded and produces little to no measurable body composition change in humans.
For Reference Only
These doses are provided for informational purposes. Matrix does not recommend this compound. Visible results are rarely achieved.
| Parameter | Details |
|---|---|
| Starting Dose | 250 mcg daily |
| Moderate Dose | 500 mcg daily |
| High Dose | 750–1000 mcg daily |
| Route | Subcutaneous injection |
| Cycle Length | 6–12 weeks |
| Typical User Experience | Rarely any visible results |
Instead of HGH Frag 176-191, Matrix recommends:
This guide is for educational and clinical-support purposes only. All dosing must be supervised by a licensed prescriber. Matrix Advanced Solutions does not provide medical advice. Always consult your healthcare provider before starting any protocol.